cadefrecitinib

Cadefrecitinib is an investigational, orally administered **small-molecule selective tyrosine kinase 2 inhibitor** being developed by Galapagos for inflammatory and autoimmune diseases. Also known as **GLPG3667**, it is described as a **reversible, ATP-competitive TYK2 inhibitor** that suppresses TYK2-dependent cytokine signaling, including IFN-alpha driven STAT1 phosphorylation, with the goal of modulating pathogenic immune responses while aiming to avoid broader JAK-family inhibition. Publicly documented clinical development has included studies in **systemic lupus erythematosus**, **dermatomyositis**, and **plaque psoriasis**, with Galapagos reporting Phase 3-enabling programs in SLE and dermatomyositis.

Other names

cadefrecitinibGLPG3667GLPG-3667GLPG 3667